Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Liabilities and Shareholders Equity (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Liabilities and Shareholders Equity data on record, last reported at $1.1 billion in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 227.48% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $2.5 billion, changed N/A, while the annual FY2025 figure was $1.1 billion, 227.48% up from the prior year.
  • Liabilities and Shareholders Equity reached $1.1 billion in Q4 2025 per CAI's latest filing, up from $984.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.1 billion in Q4 2025 and bottomed at $343.7 million in Q4 2024.